BioCentury
ARTICLE | Clinical News

MaaT completes enrollment in Phase Ib of MaaT001 for dysbiosis

August 11, 2017 2:46 PM UTC

MaaT Pharma S.A. (Lyon, France) completed enrollment of 25 acute myelogenous leukemia (AML) patients with iatrogenic dysbiosis induced by chemotherapy or antibiotics in the Phase Ib Odyssée trial eva...

BCIQ Company Profiles

MaaT Pharma S.A.